ASEAN Insight Provider, CrossASEAN Research

Angus Mackintosh

ASEAN Insight Provider

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/prodia-widyahusada" target="_blank" data-smartkarma-citation="entities:23663:1" rel="noopener">Prodia (PRDA IJ)</a> released an exceptionally strong set of FY2021 results, driven partly by COVID testing but coupled by a pick-up in its core testing business and especially esoteric testing.</li>
<li>It continues to see increasing tests per visit with revenue per visit increasing at the same time. Its digital strategy is working well further driving growth through an omnichannel approach.</li>
<li>
<a href="https://www.smartkarma.com/entities/prodia-widyahusada" target="_blank" data-smartkarma-citation="entities:23663:1" rel="noopener">Prodia (PRDA IJ)</a> continues to look dramatically undervalued versus its Indian diagnostic peers given its quality and growth prospects and remains our top Indonesian healthcare pick.</li>
</ul>



Prodia (PRDA IJ) released an exceptionally strong set of FY2021 results, driven partly by COVID testing but coupled by a pick-up in its core testing business and especially esoteric testing.
It continues to see increasing tests per visit with revenue per visit increasing at the same time. Its digital strategy is working well further driving growth through an omnichannel approach.

Prodia (PRDA IJ) continues to look dramatically undervalued versus its Indian diagnostic peers given its quality and growth prospects and remains our top Indonesian healthcare pick.


Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

Apollo Hospitals Enterprise / Event-Driven

<ul>
<li>As expected, <a href="https://www.smartkarma.com/entities/apollo-hospitals-enterprise" target="_blank" data-smartkarma-citation="entities:880:1" rel="noopener">Apollo Hospitals Enterprise (APHS IN)</a> will replace <a href="https://www.smartkarma.com/entities/indian-oil-corp-ltd" target="_blank" data-smartkarma-citation="entities:7781:1" rel="noopener">Indian Oil Corp (IOCL IN)</a> in the <a href="https://www.smartkarma.com/entities/nifty-index" target="_blank" data-smartkarma-citation="entities:23617:1" rel="noopener">NIFTY Index (NIFTY INDEX)</a> after the close of trading on 30 March.</li>
<li>The index methodology has been changed to make new listings eligible for index inclusion if they complete one month by the review cutoff date, down from three months earlier.</li>
<li>Estimated one-way turnover is 0.63% and will result in a one-way trade of around INR 14bn. Passive trackers will have a lot to trade on the stocks.</li>
</ul>


As expected, Apollo Hospitals Enterprise (APHS IN) will replace Indian Oil Corp (IOCL IN) in the NIFTY Index (NIFTY INDEX) after the close of trading on 30 March.
The index methodology has been changed to make new listings eligible for index inclusion if they complete one month by the review cutoff date, down from three months earlier.
Estimated one-way turnover is 0.63% and will result in a one-way trade of around INR 14bn. Passive trackers will have a lot to trade on the stocks.


NIFTY50 Index Rebalance: Apollo Hospitals to Replace IOC

<ul>
<li>The review period for the March rebalance of the <a href="https://www.smartkarma.com/entities/nifty-index" target="_blank" data-smartkarma-citation="entities:23617:1" rel="noopener">NIFTY Index (NIFTY INDEX)</a> ends 31 January. We see 2 potential changes at the rebalance which should be announced end February.</li>
<li>There is a high probability of <a href="https://www.smartkarma.com/entities/apollo-hospitals-enterprise" target="_blank" data-smartkarma-citation="entities:880:1" rel="noopener">Apollo Hospitals Enterprise (APHS IN)</a> replacing <a href="https://www.smartkarma.com/entities/indian-oil-corp-ltd" target="_blank" data-smartkarma-citation="entities:7781:1" rel="noopener">Indian Oil Corp (IOCL IN)</a>, while there is a lower probability of <a href="https://www.smartkarma.com/entities/info-edge-india-ltd" target="_blank" data-smartkarma-citation="entities:14461:1" rel="noopener">Info Edge India</a> replacing <a href="https://www.smartkarma.com/entities/coal-india-ltd" target="_blank" data-smartkarma-citation="entities:9117:1" rel="noopener">Coal India Ltd</a>.</li>
<li>The impact on the stocks is between 3-9 days of ADV, while the impact increases to between 9-22 days of delivery volume.</li>
</ul>


The review period for the March rebalance of the NIFTY Index (NIFTY INDEX) ends 31 January. We see 2 potential changes at the rebalance which should be announced end February.
There is a high probability of Apollo Hospitals Enterprise (APHS IN) replacing Indian Oil Corp (IOCL IN), while there is a lower probability of Info Edge India replacing Coal India Ltd.
The impact on the stocks is between 3-9 days of ADV, while the impact increases to between 9-22 days of delivery volume.


NIFTY50 Index Rebalance Preview: Two Potential Changes in March

<ul>
<li>Nearly three-quarters of the way through the review period, we see <a href="https://www.smartkarma.com/entities/apollo-hospitals-enterprise" target="_blank" data-smartkarma-citation="entities:880:1" rel="noopener">Apollo Hospitals (APHS)</a> and <a href="https://www.smartkarma.com/entities/info-edge-india-ltd" target="_blank" data-smartkarma-citation="entities:14461:1" rel="noopener">Info Edge (INFOE)</a> replacing <a href="https://www.smartkarma.com/entities/indian-oil-corp-ltd" target="_blank" data-smartkarma-citation="entities:7781:1" rel="noopener">Indian Oil (IOCL)</a> and <a href="https://www.smartkarma.com/entities/coal-india-ltd" target="_blank" data-smartkarma-citation="entities:9117:1" rel="noopener">Coal India (COAL)</a> in the NIFTY50.</li>
<li>The inclusion of Apollo Hospitals and deletion of IOC is a high probability event, while the inclusion of Info Edge and deletion of Coal India is a lower probability event.</li>
<li>The impact in terms of ADV to trade on the stocks is quite large and that increases further once we consider the impact in terms of delivery volumes.</li>
</ul>


Nearly three-quarters of the way through the review period, we see Apollo Hospitals (APHS) and Info Edge (INFOE) replacing Indian Oil (IOCL) and Coal India (COAL) in the NIFTY50.
The inclusion of Apollo Hospitals and deletion of IOC is a high probability event, while the inclusion of Info Edge and deletion of Coal India is a lower probability event.
The impact in terms of ADV to trade on the stocks is quite large and that increases further once we consider the impact in terms of delivery volumes.


NIFTY50 Index Rebalance Preview: Apollo Hospitals & Info Edge in the Zone to Replace IOC and COAL

<ul>
<li>
<a href="https://www.smartkarma.com/entities/prodia-widyahusada" target="_blank" data-smartkarma-citation="entities:23663:1" rel="noopener">Prodia (PRDA IJ)</a> registered an explosive growth in 3Q2021 boosted by higher esoteric testing but also a pick up in routine testing, which should help to drive growth into 2022.</li>
<li>The company continues to expand its network and develop its omnichannel capabilities through its Prodia app, as well as introducing new diagnostic tests to its offering </li>
<li>
<a href="https://www.smartkarma.com/entities/prodia-widyahusada" target="_blank" data-smartkarma-citation="entities:23663:1" rel="noopener">Prodia (PRDA IJ)</a> remains one of our top healthcare picks in Indonesia, which also looks very undervalued versus its Indian peers, despite its high-quality operations and growth outlook.</li>
</ul>



Prodia (PRDA IJ) registered an explosive growth in 3Q2021 boosted by higher esoteric testing but also a pick up in routine testing, which should help to drive growth into 2022.
The company continues to expand its network and develop its omnichannel capabilities through its Prodia app, as well as introducing new diagnostic tests to its offering 

Prodia (PRDA IJ) remains one of our top healthcare picks in Indonesia, which also looks very undervalued versus its Indian peers, despite its high-quality operations and growth outlook.


Prodia (PRDA IJ) - Keeping Indonesia Healthy Beyond COVID

India

Dr. Lal PathLabs Limited operates clinical laboratories. The Company offers medical diagnostic, cardiology, radiology, pathology and imaging, health checkup, blood test, and customer care services. Dr. Lal PathLabs conducts its business in India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dr Lal PathLabs Ltd (DLPL IN)

Prodia (PRDA IJ) - Diagnosed for Growth

Prodia (PRDA IJ) continues to look dramatically undervalued versus its Indian diagnostic peers given its quality and growth prospects and remains...

Angus Mackintosh

NIFTY50 Index Rebalance: Apollo Hospitals to Replace IOC

APHS will replace IOCL in the NIFTY after the close of trading on 30 March. There is a fair bit of volume to trade on the stocks from passive...

Brian Freitas

NIFTY50 Index Rebalance Preview: Two Potential Changes in March

There is a high probability of Apollo Hosp replacing Indian Oil in the NIFTY Index at the March rebalance. There is a lower probability of Info...

Brian Freitas

NIFTY50 Index Rebalance Preview: Apollo Hospitals & Info Edge in the Zone to Replace IOC and COAL

High probability changes are inclusion of Apollo Hospitals & deletion of IOCL, while there is a lower probability of Info Edge being added & COAL...

Brian Freitas

Prodia (PRDA IJ) - Keeping Indonesia Healthy Beyond COVID

Prodia (PRDA IJ) remains one of our top healthcare picks in Indonesia, which looks very undervalued versus its Indian peers, despite its high...

Angus Mackintosh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)